Aprepitant Patent Expiration
Aprepitant is Used for preventing and treating nausea and vomiting associated with chemotherapy, postoperative nausea and vomiting, and emesis induced by cancer chemotherapeutic agents. It was first introduced by Merck And Co Inc
Aprepitant Patents
Given below is the list of patents protecting Aprepitant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aponvie | US10500208 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US10953018 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US11878074 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US12290520 | Methods of use of emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9561229 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9808465 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9974793 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Aponvie | US9974794 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US10500208 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US10624850 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US10953018 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US11173118 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US11744800 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US12115254 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US12115255 | Methods of use of emulsion formulations of an NK-1 receptor antagonist | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US12290520 | Methods of use of emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9561229 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9808465 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9974742 | Emulsion formulations of an NK-1 receptor antagonist and uses thereof | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9974793 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Cinvanti | US9974794 | Emulsion formulations of aprepitant | Sep 18, 2035 | Heron Theraps Inc |
| Emend | US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | Sep 26, 2027 | Merck |
| Emend | US8258132 | Pharmaceutical composition of a tachykinin receptor antagonist | Sep 26, 2027 | Msd Merck Co |
| Emend | US6096742 | Polymorphic form of a tachykinin receptor antagonist |
Jul 01, 2018
(Expired) | Merck |
| Emend | US6096742 | Polymorphic form of a tachykinin receptor antagonist |
Jul 01, 2018
(Expired) | Msd Merck Co |
| Emend | US5719147 | Morpholine and thiomorpholine tachykinin receptor antagonists |
Apr 17, 2015
(Expired) | Merck |
| Emend | US5538982 | Medical use for tachykinin antagonists |
Jul 23, 2013
(Expired) | Merck |
| Emend | US7214692 | Medical use for tachykinin antagonists |
Sep 18, 2012
(Expired) | Merck |
Aprepitant's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List